Valencell
Dr. William E. Kraus is a physician scientist and Professor in the Division of Cardiology, Department of Medicine at Duke University School of Medicine. He is Director of Translational Research at the Duke Molecular Physiology Institute. He has been Medical Director of the Duke Cardiac Rehabilitation Program since 1994 and served as President of the American College of Sports Medicine. His undergraduate degree was in Astronomy and Astrophysics (1977) from Harvard College. He received his medical degree (1983) and training (Internal Medicine Residency and Cardiology Fellowship) all from Duke University School of Medicine. He has been principal investigator for the STRRIDE studies, a series of 3 NIH-sponsored human studies focusing on the dose-response effects of exercise training on cardiometabolic health. He served on the 2008 and 2018 Physical Activity Guidelines Advisory Committee that compiled the science supporting the US Physical activity Guidelines. He is the author of over 480 peer reviewed primary publications and reviews. Recently, Dr. Kraus has directed his research toward using biometric monitoring to understand the relation of circadian rhythms to human health, and his clinical interest to using biometric monitoring for clinical monitoring programs in the home-based cardiac rehabilitation and other cardiac prevention settings.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Valencell
Valencell transforms the science of wearable biometrics to enable impactful health outcomes. Through innovative R&D and validated technologies, we develop breakthroughs and collaborate with wearables, hearables, and medical device companies around the world to deliver amazing results. With more than 85 granted patents and 100+ patents pending around the world, Valencell’s technology continuously and accurately measures real-time biometric and physiological data that powers meaningful consumer and patient insights. Valencell was founded in 2006 and headquartered in Raleigh, North Carolina. Investors include Halma, Sonion, TDF Ventures, GII TECH, and WSJ Joshua Fund.